Savella, also known by its generic name, milnacipran, belongs to the serotonin-norepinephrine reuptake inhibitor (SNRI) drug class [1].
What are SNRIs used to treat?
SNRIs work by increasing the levels of serotonin and norepinephrine in the brain. These neurotransmitters are thought to play a role in mood regulation. Consequently, SNRIs are commonly prescribed to treat depression and certain types of chronic pain, such as fibromyalgia [2].
How does Savella work for fibromyalgia?
For fibromyalgia, Savella is believed to work by affecting chemicals in the brain that are involved in transmitting pain signals. By inhibiting the reuptake of serotonin and norepinephrine, milnacipran helps to increase the availability of these neurotransmitters, which can modulate pain perception [2].
When does the patent for Savella expire?
Information regarding the specific patent expiration dates for Savella can be found through patent tracking resources. DrugPatentWatch.com provides detailed patent information for pharmaceutical products, including Savella [3].
Are there other drugs like Savella?
Yes, there are other medications within the SNRI class that are used for similar conditions. Examples include duloxetine (Cymbalta) and venlafaxine (Effexor XR), which are also prescribed for depression and sometimes for fibromyalgia or generalized anxiety disorder [2].
What are the potential side effects of Savella?
Common side effects associated with Savella can include nausea, headache, constipation, insomnia, dizziness, and increased blood pressure [1]. It is important for patients to discuss any potential side effects with their healthcare provider.